Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
STAMFORD, Conn., April 27, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, May 4, 2017, at 4:30 p.m. ET to report first quarter 2017 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 10052639. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
